Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting future left anterior descending artery events from non-culprit lesions: insights from the Lipid-Rich Plaque study.
Kuku KO, Garcia-Garcia HM, Doros G, Mintz GS, Ali ZA, Skinner WH, Artis AK, Ten Cate T, Powers E, Wong SC, Wykrzykowska J, Dube S, Kazziha S, van der Ent M, Shah P, Sum S, Torguson R, Di Mario C, Waksman R. Kuku KO, et al. Among authors: doros g. Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):1365-1372. doi: 10.1093/ehjci/jeab160. Eur Heart J Cardiovasc Imaging. 2022. PMID: 34410335
Lipid-rich plaques detected by near-infrared spectroscopy predict coronary events irrespective of age: A Lipid Rich Plaque sub-study.
Bambagioni G, Di Mario C, Torguson R, Demola P, Ali Z, Singh V, Skinner W, Artis A, Cate TT, Zhang C, Garcia-Garcia HM, Doros G, Mintz GS, Waksman R. Bambagioni G, et al. Among authors: doros g. Atherosclerosis. 2021 Oct;334:17-22. doi: 10.1016/j.atherosclerosis.2021.08.022. Epub 2021 Aug 14. Atherosclerosis. 2021. PMID: 34455112
Greater plaque burden and cholesterol content may explain an increased incidence of non-culprit events in diabetic patients: a Lipid-Rich Plaque substudy.
Demola P, Di Mario C, Torguson R, Ten Cate T, Bambagioni G, Ali Z, Skinner W, Artis A, Zhang C, Garcia-Garcia HM, Doros G, Mintz GS, Waksman R. Demola P, et al. Among authors: doros g. Eur Heart J Cardiovasc Imaging. 2022 Jul 21;23(8):1098-1107. doi: 10.1093/ehjci/jeab161. Eur Heart J Cardiovasc Imaging. 2022. PMID: 34568945
Longitudinal Distribution of Lipid-Rich Plaque in Nonculprit Lesions: A Lipid Rich Plaque Study Subanalysis.
Shlofmitz E, Mintz GS, Torguson R, Zhang C, Shea C, Shah P, Doros G, Ali ZA, Artis A, Singh V, Skinner W, Cate TT, Di Mario C, Garcia-Garcia HM, Waksman R. Shlofmitz E, et al. Among authors: doros g. JACC Cardiovasc Imaging. 2022 Jan;15(1):168-170. doi: 10.1016/j.jcmg.2021.07.019. Epub 2021 Nov 17. JACC Cardiovasc Imaging. 2022. PMID: 34801454 Free article. No abstract available.
Near-infrared spectroscopy predicts events in men and women: Results from the Lipid Rich Plaque study.
Mensink FB, Ten Cate TJF, Damen SAJ, Roes K, Di Mario C, Singh V, Ali ZA, Skinner W, Artis A, Torguson R, Zhang C, Doros G, Garcia-Garcia HM, Mintz GS, Geuns RV, Waksman R. Mensink FB, et al. Among authors: doros g. Int J Cardiol Heart Vasc. 2022 Mar 8;39:100985. doi: 10.1016/j.ijcha.2022.100985. eCollection 2022 Apr. Int J Cardiol Heart Vasc. 2022. PMID: 35281753 Free PMC article.
Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
Roguin A, Kandzari DE, Marcusohn E, Koolen JJ, Doros G, Massaro JM, Garcia-Garcia HM, Bennett J, Gharib EG, Cutlip DE, Waksman R. Roguin A, et al. Among authors: doros g. Circ Cardiovasc Interv. 2018 Oct;11(10):e007331. doi: 10.1161/CIRCINTERVENTIONS.118.007331. Circ Cardiovasc Interv. 2018. PMID: 30354631 Clinical Trial.
Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Kandzari DE, et al. Among authors: doros g. JACC Cardiovasc Interv. 2020 Jun 8;13(11):1343-1353. doi: 10.1016/j.jcin.2020.02.019. JACC Cardiovasc Interv. 2020. PMID: 32499026 Free article. Clinical Trial.
Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: BIOFLOW V Final 5-Year Outcomes.
Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Kandzari DE, et al. Among authors: doros g. JACC Cardiovasc Interv. 2022 Sep 26;15(18):1852-1860. doi: 10.1016/j.jcin.2022.07.027. JACC Cardiovasc Interv. 2022. PMID: 36137689 Free article. Clinical Trial.
Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Kandzari DE, et al. Among authors: doros g. Lancet. 2017 Oct 21;390(10105):1843-1852. doi: 10.1016/S0140-6736(17)32249-3. Epub 2017 Aug 26. Lancet. 2017. PMID: 28851504 Clinical Trial.
306 results